Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Where does Sobi fit: with Biogen or Baxter, Novo or Pfizer?

This article was originally published in Scrip

Executive Summary

Swedish Orphan Biovitrum (SOBI) has been approached by a mystery corporate buyer, the company confirmed on 27 April. But the company has given no indication where the approach comes from. The most likely acquirer is Biogen, SOBI's US and rest-of-world partner for two hemophilia products approved in the US. But Pfizer is also a long-term partner of SOBI's in hemophilia, and hemophilia market leader Baxter has been strengthening its offering through acquisition in recent years. Novo Nordisk might also be a decent fit, if it were not for Novo's reticence about growth based on acquisition.

Topics

Related Companies

UsernamePublicRestriction

Register

SC028545

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel